Artal Group’s IGM Biosciences IGMS Stock Holding History

Artal Group’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-50,000	Closed	-$851K	–	127
2022 Q4	$851K	Hold	50,000	–	–	0.05%	105
2022 Q3	$1.14M	Hold	50,000	–	–	0.05%	110
2022 Q2	$902K	Buy	+50,000	New	+$891K	0.05%	117

Other funds holding IGMS

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artal Group's IGMS Position: Q3 2024 in Review

Artal Group sold out of IGM Biosciences (IGMS) in Q3 2024, closing a stake of 3,330,422 shares — an estimated $22.9M sold.

Artal Group first reported a position in IGMS in Q3 2019 and held it in 18 quarters. The position peaked at $106M in Q4 2020. 72 funds tracked by Wall St. Rank hold IGMS as of Q3 2024.

Artal Group reported no remaining IGM Biosciences position as of Q3 2024 after selling out during the quarter.
Artal Group sold 3,330,422 IGM Biosciences shares in Q3 2024, an estimated $22.9M.
Artal Group first reported a position in IGM Biosciences in Q3 2019 and held it in 18 quarters.
Artal Group's IGM Biosciences position peaked at $106M in Q4 2020.
72 funds tracked by Wall St. Rank held IGM Biosciences as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.